Even if the epigenetic regulation of the NFE2L2 promoter has not yet been investigated in RCC, understanding the balance between its hypomethylation and the hypermethylation of the KEAP1 promoter can be informative in the development of new therapeutic strategies. Here, NFE2L2 is linked to renal cell carcinoma.